Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors

Published: 18 December 2020

  • Views:

    Views Icon 55

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

Learning objectives

  • Understand current guidelines and utilisation of SGLT2i
  • Describe the potential mechanism of benefit of SGLT2i
  • Initiate and manage SGLT2i in appropriate patients

More from this programme

Part 1

Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice

1 session
Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice Watch now

Part 2

SGLT2i are Cardiovascular Drugs

1 session
SGLT2i are Cardiovascular Drugs Watch now

Part 3

Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice?

1 session
Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice? Watch now

Part 4

Case Discussion

1 session
Case Discussion Watch now

Part 5

A Follow-up Discussion to the ESC 2020 Session

1 session
A Follow-up Discussion to the ESC 2020 Session Watch now

Faculty Biographies

Shelley Zieroth

Shelley Zieroth

University of Manitoba, Canada

Dr Shelley Zieroth is currently at SBH Heart Failure and Transplant Clinics and serves as Head of the Medical Heart Failure Program, WRHA Cardiac Sciences Program, and as Associate Professor of the Section of Cardiology at the University of Manitoba, Canada.

View full profile
Stefan Anker

Stefan Anker

Professor of Cardiology

Dr Stefan D Anker, Professor of Cardiology and Cachexia Research, Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany, and served as the 2012–14 President of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). 

View full profile